In this operation, Invest Securities intervened as bookrunner and Invest Corporate Finance intervened as advisor.
Paris, 4th of April 2017: A biotechnology company listed on the Alternext market of Euronext Paris, Biophytis specializes in age-related diseases. Biophytis secures funding to conduct its phase 2B SARA-OBS / SARA-INT clinical trials, with the intention of testing its flagship product Sarconeos for the treatment of Sarcopenia.
Description of the financial transaction:
- Completes a €3.7M private placement
- Arranges a bond financing of up to €15M
This operation combines a private placement through a capital increase of €3.7M (of which €1M subscribed by Bracknor Fund Ltd) and a bond financing of €15M provided by Bracknor Fund Ltd (bonds redeemable in cash or new or existing shares combined with Share Subscription Warrants).
Participants in the operation
For Invest Corporate Finance : Vincent Déchin, Jean-Emmanuel Vernay, Christine Lambert-Goué, Maxime Bazin
For Invest Securities : Pascal Hadjedj
About BIOPHYTIS:
Biophytis SA (www.biophytis.com ), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.
BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825).
For more information: http://www.biophytis.com
Follow us on Twitter @biophytis
BIOPHYTIS is eligible for the SMEs scheme
About Invest Securities
A provider of multi-expert investment services, Invest Securities is one of the structures of the independent financial corporation Allinvest. With complimentary business centers: brokerage, analysis office and issuer service, Invest Securities brings global and personalised solutions to businesses, institutional investors as well as fund managers. Having led more than 200 operations over the last 10 years, Invest Securities has positioned itself as the foremost introducer (in number of operations) on the Euronext and Alternext markets. Already high ranking in several sectors like reals estate and growth businesses, Invest Securities has recently reinforced its teams in the domains of new technology, large scale distribution, luxury goods and media and is today monitoring more than 120 values.
About Invest Corporate Finance
Part of the independent financial corporation Allinvest, Invest Corporate Finance develops advisory activities in financial engineering for listed and non-listed companies and their familial or financial shareholders. The Invest Corporate Finance team consists of 25 professionals and has carried out more than 350 operations (LBO, increase of capital, cession, acquisition…) in the mid-market sector (PME-ETI) since 2006, of which close to fifty were at an international level (primarily in Asia, in the US and in Europe).
| Press Contacts
Daiana Hirte // daiana.hirte@citigate.fr – 01 53 32 78 90 Kristell Le Nadan // kristell.lenadan@citigate.fr – 01 53 32 84 71 |
Invest Securities / Invest Corporate Finance Contact
Virginie Vergara // vvergara@all-invest.com – 01 44 88 77 99 |
